Insurers Support CMS Plan To Gather Evidence On Genetic Warfarin Tests
This article was originally published in The Gray Sheet
Executive Summary
Two groups of private insurers support CMS' proposal to not cover routine pharmacogenomic testing for response to the blood-thinner warfarin